Related Experiment Video

Updated: Jul 1, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients

E Santini1, S Madec, V Corretti

  • 1Department of Internal Medicine, University of Pisa, I-56100 Pisa, Italy.

Journal of Endocrinological Investigation
|September 13, 2008
PubMed

Insights

Rosuvastatin, but not simvastatin, reduced soluble CD40 ligand (sCD40L) levels in patients with Type 2 diabetes and hypercholesterolemia. This suggests rosuvastatin may offer additional benefits beyond lipid lowering by targeting vascular inflammation.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Hypercholesterolemia and Type 2 diabetes are significant cardiovascular disease risk factors.
  • Subclinical inflammation and hypercoagulability contribute to cardiovascular risk.
  • Soluble CD40 ligand (sCD40L) indicates vascular inflammation and predicts damage in Type 2 diabetes.

Purpose of the Study:

  • To compare the anti-inflammatory effects of short-term rosuvastatin versus simvastatin treatment.
  • To evaluate the impact of these statins on markers of inflammation and vascular damage in diabetic patients.
  • To investigate the specific effect on soluble CD40 ligand (sCD40L) levels.

Main Methods:

  • A 12-week study involving 36 patients with Type 2 diabetes and moderate hypercholesterolemia.
  • Treatment groups received either rosuvastatin or simvastatin.
  • Key markers assessed included lipid profile, albumin excretion rate, urinary N-acetyl-beta-D-glucosaminidase, homocysteine, interleukin-6, C-reactive protein, and sCD40L.

Main Results:

  • Both statins improved lipid profiles and reduced albumin excretion rate.
  • C-reactive protein levels decreased with both treatments.
  • Rosuvastatin significantly reduced sCD40L, while simvastatin did not; systolic blood pressure correlated with sCD40L changes.

Conclusions:

  • Short-term rosuvastatin treatment effectively reduces sCD40L in hypercholesterolemic Type 2 diabetic patients.
  • Rosuvastatin may offer advantages in managing vascular inflammation beyond lipid reduction.
  • sCD40L reduction by rosuvastatin is linked to improvements in systolic blood pressure.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...